Drugs / ALK-N001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07529535 | Jun 2025 → Dec 2026 | — | Zhejiang Anglikang Pharmaceutical Co., Ltd. | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07509684 | Apr 2026 → Dec 2027 expected | cancer | Zhejiang Anglikang Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALK-N001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07529535 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT07509684 ↗ |